ArticleJournal of biopharmaceutical statistics2020
The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations.
Article in Journal of biopharmaceutical statistics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- PrecISE-a biomarker-stratified adaptive trial of 5 interventions in severe asthma: Final protocol and the baseline cohort.The Journal of allergy and clinical immunology · 2026Trial
- High Interleukin (IL)-6 is Associated with Lower Lung Function and Increased Likelihood of Metabolic Dysfunction in Asthma.Pulmonary therapy · 2025Article
- Covariate-adaptive biased coin randomization for master protocols with multiple interventions and biomarker-stratified allocation.Statistics in biopharmaceutical research · 2024Article
- Inference on subgroups identified based on a heterogeneous treatment effect in a post hoc analysis of a clinical trial.Clinical trials (London, England) · 2023Article
- Clinical Trial Design Innovations for Precision Medicine in Asthma.Advances in experimental medicine and biology · 2023Article
- The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions.The Journal of allergy and clinical immunology · 2022Review
- Advancing precision medicine for acute respiratory distress syndrome.The Lancet. Respiratory medicine · 2022Review
- PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment.The Journal of allergy and clinical immunology · 2021Article
- Unlocking immune-mediated disease mechanisms with transcriptomics.Biochemical Society transactions · 2021Review
- NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2021Review
- National Asthma Education and Prevention Program 2020 Guideline Update: Where Do We Go from Here?American journal of respiratory and critical care medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors at 20 institutions in 1 country.
Funding
Abstract
The Precision Interventions for Severe and/or Exacerbation-prone Asthma (PrecISE) study is an adaptive platform trial designed to investigate novel interventions to severe asthma. The study is conducted under a master protocol and utilizes a crossover design with each participant receiving up to five interventions and at least one placebo. Treatment assignments are based on the patients' biomarker profiles and precision health methods are incorporated into the interim and final analyses. We describe key elements of the PrecISE study including the multistage adaptive enrichment strategy, early stopping of an intervention for futility, power calculations, and the primary analysis strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.